| Literature DB >> 31240424 |
Judith A Eelloo1, Miriam J Smith2,3, Naomi L Bowers2, John Ealing2,4, Paul Hulse5, James P Wylie6, Patrick Shenjere7, Noel W Clarke8, Calvin Soh9, Richard W Whitehouse9, Mark Jones10, Christopher Duff11, Anthony Freemont12, D Gareth Evans2,3.
Abstract
A 51-year old presented with a 6-month history of increasing pelvic/lower back pain with nocturnal waking and episodes of anorexia and vomiting. Examination revealed right torticollis and Horner's syndrome, and a large abdominal mass arising from the pelvis. Magnetic resonance and positron emission tomography imaging revealed (A) a 14 cm heterogeneous enhancing mass, abutting the left kidney with standardised uptake value max = 2.9, (B) a large heterogeneous enhancing pelvic mass (C) mesenteric adenopathy standardised uptake value max = 10.3 and (D) 6 cm right lung apex mass standardised uptake value max = 4.3. Computerised tomography-guided biopsy of lesion A was reported as neurofibroma with occasional atypia, lesion B a benign uterine leiomyoma and lesion C follicular lymphoma world health organisation Grade 2. Although she had been given the diagnosis of Neurofibromatosis Type-1 (NF1) 25-years previously following removal of an intradural extramedullary schwannoma she had no cutaneous stigmata of NF1. Genetic analysis of blood lymphocyte DNA identified a pathogenic variant in SMARCB1 confirming a diagnosis of schwannomatosis. Following 6-months chemotherapy for lymphoma, surgery was performed to remove lesion A. Histology revealed a malignant peripheral nerve sheath tumour with areas of low and high-grade change. An incidental, well-differentiated small bowel neuroendocrine carcinoma was also excised. Close surveillance continues with no recurrence after 6 years. This case study describes a novel finding of three separate synchronous primary malignancies in a patient with schwannomatosis and a proven SMARCB1 pathogenic variant.Entities:
Keywords: Follicular lymphoma; MPNST; Malignancy; Neurofibromatosis type 1; Neurofibromatosis type 2; SMARCB1; Schwannomatosis
Mesh:
Substances:
Year: 2019 PMID: 31240424 DOI: 10.1007/s10689-019-00138-4
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375